Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Simon Cheesman"'
Autor:
Simon Cheesman
Publikováno v:
HemaSphere, Vol 5, Iss 1, p e515 (2021)
Externí odkaz:
https://doaj.org/article/5e949d3185fa4c128bff25a1197a9b7a
Autor:
Neil Rabin, Iona J Blakeney, Julian D. Gillmore, Oliver C Cohen, Sajitha Sachchithanantham, Simon Cheesman, Raakhee Shah, Sriram Ravichandran, Kwee Yong, Carol J. Whelan, Rakesh Popat, Helen J. Lachmann, Ashutosh D. Wechalekar, Steven Law, Maximillian H Brodermann, Charalampia Kyriakou, Shameem Mahmood, Philip N. Hawkins, Sarah Worthington
Publikováno v:
Amyloid. 27:200-205
Background: Daratumumab is a monoclonal antibody, which targets CD38; an antigen expressed on malignant plasma cells in AL amyloidosis thus providing a rationale for its use.Method: Patients treated with daratumumab monotherapy (2016-2019) for relaps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cff9219813ff66df57c4624bcc2ca180
https://doi.org/10.1080/13506129.2020.1765768
https://doi.org/10.1080/13506129.2020.1765768
Autor:
Ashutosh D. Wechalekar, Carol J. Whelan, Charalampia Kyriakou, Ana Martinez-Naharro, Neil Rabin, Raakhee Shah, Sajitha Sachchithanantham, Shameem Mahmood, Julian D. Gillmore, Simon Cheesman, Faye Sharpley, Philip N. Hawkins, Kwee Yong, Oliver C Cohen, Helen J. Lachmann, Marianna Fontana, Rakesh Popat
Publikováno v:
British Journal of Haematology. 189:643-649
With improving outcomes in amyloid light-chain (AL) amyloidosis, there is a need to study novel agents in this setting. We report outcomes of 40 patients with relapsed AL amyloidosis treated with ixazomib + lenalidomide + dexamethasone (IRd). Haemato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8d3a9c110835ff19eee2a8a368a4b4c
https://doi.org/10.1111/bjh.16401
https://doi.org/10.1111/bjh.16401
Autor:
Matthew J. Stubbs, John P. Westwood, Mari Thomas, Ryan Low, Siobhan McGuckin, Rosalind Newton, Simon Cheesman, Marie Scully, Raakhee Shah
Publikováno v:
British Journal of Haematology. 185:912-917
Immune thrombotic thrombocytopenic purpura (iTTP) is an acute, multisystem thrombotic microangiopathy mediated by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) autoantibodies. Immunosuppression with anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7374712c014f5054da78ec50be506886
https://doi.org/10.1111/bjh.15874
https://doi.org/10.1111/bjh.15874
Autor:
Rakesh Popat, Jonathan Sive, Xenofon Papanikolaou, Shameem Mahmood, Gabrielle Lawson, Sajitha Sachchithananthan, Neil Rabin, Simon Cheesman, Kwee Yong, Dunnya De-Silva, Charalampia Kyriakou, Monica Ziff, Ashutosh D. Wechalekar
Publikováno v:
Leukemialymphoma. 62(5)
A number of new treatments have been approved for patients with multiple myeloma (MM) and the survival of patients continues to improve. However, discrepancies in outcomes of clinical trials and th...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df0354f991990067928dd6ecd9bee358
https://pubmed.ncbi.nlm.nih.gov/33439062
https://pubmed.ncbi.nlm.nih.gov/33439062
Autor:
Simon Cheesman, Nicholas Counsell, X. Papanikolaou, Jackie Horder, Jonathan Sive, Louise Ainley, Neil Rabin, Fiona Newrick, Ashutosh D. Wechalekar, Kwee Yong, Atul Mehta, Charalampia Kyriakou, Rakesh Popat, Lydia Lee, Selina J Chavda
Publikováno v:
British journal of haematologyReferences. 192(3)
Routine use of novel agents to treat newly diagnosed and relapsed multiple myeloma (MM) produces high response rates and improved survival. However, 15–20% of patients have suboptimal responses and their management remains challenging.1 Traditional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5030163a76d52ace2251aef6bfad1206
https://pubmed.ncbi.nlm.nih.gov/33236352
https://pubmed.ncbi.nlm.nih.gov/33236352
Autor:
Kwee Yong, Rachael Pocock, Selina J Chavda, Charalampia Kyriakou, Daniel Marks, Lydia Lee, Emma Dowling, Rakesh Popat, Neil Rabin, Kyung‐Min Lee, Simon Cheesman, Jonathan Sive, Ashutosh D. Wechalekar
Publikováno v:
British Journal of Haematology. 190
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::308a6e096c0d4ec1abe3d49548981e31
https://doi.org/10.1111/bjh.16889
https://doi.org/10.1111/bjh.16889
Autor:
Sajitha Sachchithanantham, Ashutosh D. Wechalekar, Kwee Yong, Mark A. Smith, Rakesh Popat, Helen J. Lachmann, Richa Manwani, Sarah Worthington, Raakhee Shah, Julian D. Gillmore, Neil Rabin, Simon Cheesman, Shameem Mahmood, Faye Sharpley, Philip N. Hawkins, Charalampia Kyriakou
Publikováno v:
British journal of haematologyReferences. 187(5)
Bortezomib is standard treatment in AL amyloidosis (AL), but is contraindicated in patients with significant neuropathy. Carfilzomib, a second-generation proteosomal inhibitor, results in a lower incidence of neuropathy than bortezomib, but data in A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8525ce5de503cbdd9c60fd78a445e701
https://pubmed.ncbi.nlm.nih.gov/31388995
https://pubmed.ncbi.nlm.nih.gov/31388995
Publikováno v:
British journal of haematology. 186(1)
The complement inhibitor, eculizumab, has revolutionised the management of atypical haemolytic uraemic syndrome (aHUS), although the optimum treatment duration is debated. Twenty-two cases of acute aHUS managed with eculizumab were retrospectively re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d979238f2d4d5e4ff6146b7929197420
https://pubmed.ncbi.nlm.nih.gov/30916388
https://pubmed.ncbi.nlm.nih.gov/30916388
